Leverage is low with debt-to-equity at 0.05 and cash of $267.5M against $79.6M of total liabilities, though the shrinking asset base and deeply negative retained earnings suggest investors should monitor dilution exposure.
Standard BioTools Inc. (LAB) balance sheet — 20-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 |
|---|
| Total Current Assets | 497.3M | 454.26M | 375.88M | 158.22M | 208.81M | 72.07M | 117.66M | 96.1M | 127.11M | 94.8M | 96.67M | 144.09M | 155.9M | 104.58M | 101.21M | 70.03M | 20.88M | 28.48M | 29.23M | 50.33M | 31.09M |
| Cash & Short-Term Investments | 461.11M | 187.57M | 292.87M | 114.89M | 165.78M | 28.45M | 68.52M | 58.64M | 95.4M | 63.14M | 59.43M | 94.97M | 115.3M | 84.34M | 80.01M | 53.47M | 5.72M | 14.6M | 17.8M | 40.36M | 25.52M |
| Cash Only | 267.49M | 118.21M | 166.73M | 51.7M | 81.31M | 28.45M | 68.52M | 21.66M | 95.4M | 58.06M | 35.05M | 29.12M | 33.71M | 35.26M | 58.65M | 13.55M | 5.72M | 14.6M | 17.8M | 34.08M | 25.02M |
| Short-Term Investments | 193.62M | 69.36M | 126.15M | 63.19M | 84.47M | 0 | 0 | 36.98M | 0 | 5.08M | 24.39M | 65.86M | 81.59M | 49.08M | 21.36M | 39.91M | 0 | 0 | 0 | 6.29M | 500K |
| Accounts Receivable | 12.98M | 13.43M | 33.61M | 19.66M | 17.28M | 18.32M | 25.42M | 18.98M | 16.65M | 15.05M | 14.61M | 25.46M | 22.38M | 10.55M | 12.9M | 9.25M | 8.1M | 8.69M | 4.71M | 1.9M | 1.76M |
| Days Sales Outstanding | 63.55 | 57.45 | 70.32 | 67.48 | 64.39 | 51.21 | 67.17 | 59.09 | 53.8 | 53.89 | 51.06 | 81 | 70.16 | 54.11 | 89.97 | 78.79 | 88.1 | 124.82 | 111.92 | 95.33 | 100.69 |
| Inventory | 17.62M | 19.98M | 40.74M | 20.53M | 21.47M | 20.82M | 19.69M | 13.88M | 13M | 15.09M | 20.11M | 17.92M | 15.99M | 8.15M | 7.17M | 5.97M | 4.89M | 3.94M | 5.46M | 5.5M | 3.04M |
| Days Inventory Outstanding | 161.09 | 170.45 | 164.9 | 134.09 | 128.7 | 124.19 | 131.1 | 95.68 | 92.49 | 110.24 | 159.57 | 140.3 | 136.22 | 148.1 | 170.75 | 165.19 | 154.21 | 125.36 | 238.1 | 571.08 | 399.88 |
| Other Current Assets | 5.59M | 233.28M | 8.66M | 3.13M | 4.28M | 16K | 0 | 0 | 2.05M | 1.53M | 2.52M | 0 | 0 | 1.54M | 0 | 1.34M | 2.17M | 0 | 0 | 500K | 0 |
| Total Non-Current Assets | 138.03M | 113.49M | 236.46M | 164.85M | 181.5M | 203.15M | 207.09M | 168.72M | 176.54M | 192.55M | 209.72M | 226.97M | 251.66M | 12.33M | 12.52M | 9.29M | 3.92M | 3.67M | 3.13M | 4.45M | 5.4M |
| Property, Plant & Equipment | 36.32M | 46.01M | 71.38M | 54.85M | 59.53M | 65.15M | 55.65M | 12.92M | 8.82M | 12.3M | 16.52M | 15.26M | 13.89M | 6.82M | 4.97M | 3.26M | 2.33M | 1.93M | 2.78M | 3.38M | 4.07M |
| Fixed Asset Turnover | 2.05x | 1.85x | 2.44x | 1.94x | 1.65x | 2.00x | 2.48x | 9.08x | 12.80x | 8.29x | 6.32x | 7.52x | 8.38x | 10.44x | 10.52x | 13.16x | 14.42x | 13.17x | 5.53x | 2.15x | 1.57x |
| Goodwill | 0 | 0 | 111.3M | 106.32M | 106.25M | 106.38M | 106.56M | 104.11M | 104.11M | 104.11M | 104.11M | 104.11M | 104.11M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 28.95M | 1.4M | 12.6M | 27.93M | 42.22M | 49.13M | 57.4M | 68.6M | 79.8M | 91.05M | 102.2M | 1.24M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 262.58M | 25.7M | 0 | 0 | 0 | 1M | 0 | 0 | 0 | 0 | 0 | 6.49M | 27.5M | 1.94M | 3.67M | 2.84M | 1.34M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 3.19M | 3.15M | 24.83M | 2.29M | 3.11M | 3.69M | 2.66M | 2.56M | 6.21M | 7.54M | 9.29M | 10.06M | 3.97M | 3.57M | 3.88M | 3.2M | 252K | 1.74M | 352K | 1.07M | 1.34M |
| Total Assets | 635.33M | 567.75M | 612.34M | 323.07M | 390.31M | 275.21M | 324.76M | 264.81M | 303.65M | 287.35M | 306.39M | 371.06M | 407.56M | 116.92M | 113.73M | 79.33M | 24.8M | 32.15M | 32.35M | 54.78M | 36.49M |
| Asset Turnover | 0.14x | 0.15x | 0.28x | 0.33x | 0.25x | 0.47x | 0.43x | 0.44x | 0.37x | 0.35x | 0.34x | 0.31x | 0.29x | 0.61x | 0.46x | 0.54x | 1.35x | 0.79x | 0.47x | 0.13x | 0.18x |
| Asset Growth % | 33.33% | -7.28% | 89.54% | -17.23% | 41.82% | -15.26% | 22.64% | -12.79% | 5.67% | -6.22% | -17.43% | -8.96% | 248.59% | 2.8% | 43.37% | 219.85% | -22.87% | -0.62% | -40.93% | 50.1% | - |
| Total Current Liabilities | 51.02M | 108.31M | 65.89M | 109.33M | 43.44M | 49.57M | 54.25M | 32.82M | 37.58M | 33.47M | 29.5M | 30.08M | 29.39M | 17.25M | 11.6M | 20.17M | 18.51M | 7.13M | 8.52M | 11.57M | 7.15M |
| Accounts Payable | 3.45M | 5.41M | 12.28M | 9.24M | 7.91M | 10.6M | 9.22M | 5.15M | 4.03M | 4.21M | 3.97M | 6.09M | 5.92M | 4.35M | 2.56M | 4.01M | 3.15M | 2.22M | 2.86M | 2.73M | 1.19M |
| Days Payables Outstanding | 58.07 | 46.12 | 49.72 | 60.32 | 47.43 | 63.22 | 61.39 | 35.5 | 28.64 | 30.77 | 31.47 | 47.7 | 50.42 | 79.12 | 60.85 | 110.96 | 99.44 | 70.67 | 124.81 | 283.05 | 156.37 |
| Short-Term Debt | 5.69M | 5.49M | 0 | 59.53M | 2.08M | 6.84M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.92M | 7.69M | 0 | 1.03M | 3.83M | 3.48M |
| Deferred Revenue (Current) | 73.62M | 38.95M | 18.59M | 16.73M | 14.44M | 15.48M | 16.39M | 11.8M | 11.46M | 10.24M | 9.16M | 9.42M | 6.93M | 2.72M | 1.89M | 2.01M | 1.34M | 758K | 1.41M | 2.65M | 1.01M |
| Other Current Liabilities | 28.8M | 58.46M | 14.71M | 12.05M | 3.96M | 8.67M | 11.21M | 3.84M | 7.62M | 10.54M | 12.37M | 3.55M | 6.87M | 5.39M | 2.88M | 2.79M | 1.05M | 616K | 141K | 468K | 223K |
| Current Ratio | 9.75x | 4.19x | 5.70x | 1.45x | 4.81x | 1.45x | 2.17x | 2.93x | 3.38x | 2.83x | 3.28x | 4.79x | 5.31x | 6.06x | 8.73x | 3.47x | 1.13x | 4.00x | 3.43x | 4.35x | 4.35x |
| Quick Ratio | 9.40x | 4.01x | 5.09x | 1.26x | 4.31x | 1.03x | 1.81x | 2.50x | 3.04x | 2.38x | 2.60x | 4.19x | 4.76x | 5.59x | 8.11x | 3.18x | 0.86x | 3.44x | 2.79x | 3.87x | 3.92x |
| Cash Conversion Cycle | 166.57 | 181.77 | 185.51 | 141.26 | 145.66 | 112.17 | 136.88 | 119.27 | 117.65 | 133.36 | 179.15 | 173.6 | 155.95 | 123.09 | 199.86 | 133.02 | 142.87 | 179.51 | 225.21 | 383.36 | 344.2 |
| Total Non-Current Liabilities | 28.56M | 35.15M | 74.73M | 361.79M | 428.33M | 131.05M | 131.46M | 78.38M | 193.95M | 222.94M | 223.66M | 226.08M | 227.75M | 2.55M | 1.48M | 2.26M | 195.46M | 198.64M | 182.17M | 173.53M | 135.51M |
| Long-Term Debt | 300K | 299K | 299K | 3.98M | 62.81M | 64.21M | 54.22M | 53.82M | 172.06M | 195.24M | 194.95M | 195.68M | 195.46M | 0 | 0 | 1.22M | 10.14M | 14.46M | 14.18M | 10.53M | 22.43M |
| Capital Lease Obligations | 91.7M | 25.04M | 26.47M | 30.37M | 34.08M | 37.55M | 38.18M | 4.32M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -184.55M | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 3.28M | 810K | 1.08M | 841K | 1.05M | 4.33M | 8.7M | 11.49M | 13.71M | 16.92M | 21.14M | 23.59M | 26.15M | 0 | 0 | 0 | 184.55M | 183.84M | 167.54M | 162.08M | -17.55M |
| Other Non-Current Liabilities | 1.12M | 1.21M | 6.96M | 312.32M | 312.21M | 882K | 1.33M | 573K | 1.85M | 5.83M | 3.26M | 2.4M | 1.79M | 651K | 237K | 374K | -184.21M | 79K | 144K | 163K | 112.3M |
| Total Liabilities | 79.58M | 143.46M | 140.62M | 471.12M | 471.78M | 180.62M | 185.71M | 111.2M | 231.53M | 256.42M | 253.16M | 256.16M | 257.14M | 19.8M | 13.07M | 22.43M | 213.97M | 205.77M | 190.69M | 185.11M | 142.66M |
| Total Debt | 26.83M | 30.83M | 33M | 98.21M | 102.66M | 111.65M | 95.38M | 59.98M | 172.06M | 195.24M | 194.95M | 195.68M | 195.46M | 0 | 0 | 10.14M | 17.82M | 14.46M | 15.21M | 14.36M | 25.91M |
| Net Debt | -240.65M | -87.39M | -133.73M | 46.51M | 21.35M | 83.2M | 26.86M | 38.32M | 76.66M | 137.18M | 159.91M | 166.57M | 161.74M | -35.26M | -58.65M | -3.42M | 12.1M | -141K | -2.58M | -19.72M | 892K |
| Debt / Equity | 0.05x | 0.07x | 0.07x | - | - | 1.18x | 0.69x | 0.39x | 2.39x | 6.31x | 3.66x | 1.70x | 1.30x | - | - | 0.18x | - | - | - | - | - |
| Debt / EBITDA | -0.38x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 3.37x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -16186.40x | -3718.31x | -40.71x | -15.25x | -43.55x | -15.65x | -14.15x | -14.59x | -3.42x | -9.95x | -12.78x | -8.43x | -9.80x | -1169.64x | -29.08x | -6.19x | -6.79x | -5.67x | -13.60x | -8.08x | -9.42x |
| Total Equity | 555.75M | 424.29M | 471.72M | -148.05M | -81.47M | 94.6M | 139.05M | 153.61M | 72.12M | 30.93M | 53.23M | 114.9M | 150.42M | 97.12M | 100.66M | 56.9M | -189.17M | -173.62M | -158.34M | -130.33M | -106.17M |
| Equity Growth % | 79.63% | -10.05% | 418.62% | -81.73% | -186.12% | -31.97% | -9.48% | 113.01% | 133.12% | -41.89% | -53.67% | -23.61% | 54.88% | -3.52% | 76.91% | 130.08% | -8.96% | -9.65% | -21.49% | -22.75% | - |
| Book Value per Share | 1.41 | 1.11 | 1.34 | -1.87 | -1.04 | 1.25 | 1.93 | 2.30 | 1.82 | 0.94 | 1.84 | 4.00 | 5.42 | 3.81 | 4.55 | 3.19 | -9.97 | -100.01 | -95.79 | -68.96 | -56.18 |
| Total Shareholders' Equity | 555.75M | 424.29M | 471.72M | -148.05M | -81.47M | 94.6M | 139.05M | 153.61M | 72.12M | 30.93M | 53.23M | 114.9M | 150.42M | 97.12M | 100.66M | 56.9M | -189.17M | -173.62M | -158.34M | -130.33M | -106.17M |
| Common Stock | 413K | 404K | 396K | 83K | 80K | 77K | 75K | 70K | 49K | 39K | 29K | 29K | 28K | 26K | 25K | 20K | 2K | 2K | 2K | 10K | 9K |
| Retained Earnings | -1.15B | -1.26B | -1.19B | -1B | -926.1M | -736M | -676.76M | -623.64M | -558.85M | -500.2M | -439.48M | -363.49M | -310.18M | -257.35M | -240.82M | -221.8M | -199.33M | -182.43M | -163.3M | -133.8M | -108.27M |
| Treasury Stock | -46.47M | -46.47M | -46.47M | -5.98M | -563K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 354K | -1.49M | 1.23M | -2.22M | -1.9M | -907K | 112K | -582K | -687K | -574K | -760K | -1.14M | -794K | -730K | -769K | -754K | -778K | -504K | -556K | -135K | -17K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying LAB stock.
As of 2025, Standard BioTools Inc. (LAB) had total assets of $567.8M including $454.3M in current assets.
Standard BioTools Inc. (LAB) carries total debt of $30.8M, offset by $187.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Standard BioTools Inc. (LAB) has total shareholders' equity (book value) of $424.3M ($1.11 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Standard BioTools Inc. (LAB) reported a current ratio of 4.19x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Persistent operating burn and deficit
Metrics are mathematically derived from official filings.
Shrinking Asset Base Masks Deleveraging
According to reported quarterly figures, LAB total assets declined from $708.7M in 2024Q2 to $635.3M in 2026Q3, a contraction of roughly 10%, while total liabilities fell from $198.5M to $79.6M, suggesting the balance sheet is contracting rather than growing.
Much of the liability reduction reflects debt repayment from roughly $90M to under $30M and a sharp drop in deferred revenue, which suggests obligations were retired rather than refinanced. The goodwill balance falling from $111M to zero points to impairment-driven shrinkage, meaning part of the asset decline is non-cash and does not reflect operating reinvestment. Investors should monitor whether the smaller asset base can support revenue stabilization without further write-downs.
Debt Reduced to Minimal Leverage
As reported in the balance sheets, LAB total debt dropped from $90.5M in 2024Q2 to $26.8M in 2026Q3, lowering debt-to-equity from 0.18 to 0.05 and leaving leverage low relative to equity.
The steep decline appears to reflect repayment rather than a shift toward cheaper financing, and the reported figures do not disclose the terms or maturity profile of the remaining obligations. With D/E at 0.05, leverage is unlikely to be the binding constraint, so the analytical focus shifts to whether operating cash generation can service the business without relying on the balance sheet. Further review of the debt schedule would be warranted before drawing firm conclusions about refinancing risk.
Cash Buffer Solid but Burn Erodes It
Based on LAB's reported balance sheets, cash stood at $267.5M in 2026Q3 against a current ratio of 9.75, a liquidity position that appears substantial relative to $79.6M of total liabilities.
The high current ratio is partly a function of a small current liabilities base, so cash runway against continuing operating losses is the more meaningful measure. Cash moved from $270.0M in 2026Q2 to $267.5M in 2026Q3, but fell sharply from roughly $265M in 2026Q1 to $118M in 2025Q4, a movement that warrants investigation given the reported figures. The buffer looks adequate in the near term, but its trajectory depends on whether operating burn persists at recent levels.
Asset Base Shifting Away From Plant
Based on reported figures, LAB's net PP&E fell from $74.1M in 2024Q2 to $36.3M in 2026Q3, suggesting the asset base is becoming less capital-intensive as cash and receivables take a larger share of total assets.
The PP&E decline alongside the disappearance of reported goodwill points to a balance sheet increasingly weighted toward liquid and working-capital assets rather than long-lived operating assets. This profile is consistent with an asset-light position, though it may also reflect reduced manufacturing capacity relative to the prior period. The reported data does not identify the drivers of the PP&E reduction, so the operational implications remain open for further review.
Headline Cash Masks Thin Recurring Base
As reported in the balance sheets, LAB's $267.5M cash balance and 9.75 current ratio look strong, yet retained earnings near -$1.1B suggest equity is sustained by paid-in capital rather than earned profits, which may understate dilution exposure.
A large cash position funded largely by external capital can look like a fortress while masking a history of cumulative losses that has not been reversed by operations. The reported data does not break out stock-based compensation or share issuance, so the extent of ongoing dilution cannot be fully assessed from the balance sheet alone. Investors should monitor future share issuance and cash burn against the accumulated deficit to judge whether the liquidity cushion is durable.